Phase III Randomized Study of TAX/CBDCA vs CBDCA or CAP (CTX/DOX/CDDP) for Advanced Ovarian Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Alternate Title

Chemotherapy in Treating Women With Advanced Ovarian Cancer

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentClosedany ageMRC-ICON3


I.  Compare the overall and progression-free survival and complete response 
rate in women with advanced ovarian cancer treated with paclitaxel/carboplatin 
vs. a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin, 
cisplatin) as first-line therapy.

II.  Assess patient quality of life in relation to treatment-related toxicity 
and anxiety and depression.

III.  Compare treatment costs during the first 6 months of study.

Entry Criteria

Disease Characteristics:

Histologically and clinically diagnosed invasive epithelial ovarian carcinoma

Prior/Concurrent Therapy:

Biologic therapy:
  Not specified

  No prior chemotherapy

Endocrine therapy:
  Not specified

  No prior radiotherapy

  Recommended minimum surgical procedures (if possible):
     Total hysterectomy and bilateral salpingo-oophorectomy (as appropriate)

Patient Characteristics:

  Not specified

Performance status:
  Not specified

  Not specified

  Bilirubin less than 2 x normal

  Not specified

  No sepsis
  No contraindication to platinum-based chemotherapy

Expected Enrollment

A maximum of 2,000 patients will be entered.


Randomized study.  Patients are randomized 1:2 to Arms I and II.  The choice 
of control treatment on Arm II must be made prior to randomization and is at 
the discretion of the investigator and the patient.

The following acronyms are used:
    CAP        CTX/DOX/CDDP
    CBDCA      Carboplatin, NSC-241240
    CDDP       Cisplatin, NSC-119875
    CTX        Cyclophosphamide, NSC-26271
    DOX        Doxorubicin, NSC-123127
    TAX        Paclitaxel (Bristol-Myers Squibb), NSC-125973

Arm I:  2-Drug Combination Chemotherapy.  TAX/CBDCA.

Arm II:  Single-Agent or 3-Drug Combination Chemotherapy.  CBDCA or CAP.

Published Results

Colombo N: Randomised trial of paclitaxel (PTX) and carboplatin (CBDCA) versus a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin & cisplatin): The Third International Collaborative Ovarian Neoplasm study (ICON3). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1500, 2000.

Harper P: A Randomised Comparison of Paclitaxel (T) and Carboplatin (J) Versus a Control Arm of Single Agent Carboplatin (J) or CAP (cyclophosphamide, Doxorubicin and Cisplatin): 2075 Patients Randomised Into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3) (Meeting abstract). [Abstract] Proceedings of the American Society of Clinical Oncology 18: A-1375, 1999.

Poole CJ: A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or cyclophosphamide, doxorubicin and cisplatin (CAP): 2074 patients randomised into the 3rd International Collaborative Ovarian Neoplasm study (ICON3). [Abstract] Br J Cancer 80 (suppl 2): A-2.11, 14, 1999.

Related Publications

Colombo N, Parma G, Bocciolone L, et al.: Medical therapy of advanced malignant epithelial tumours of the ovary. Forum (Genova) 10 (4): 323-32, 2000 Oct-Dec.[PUBMED Abstract]

Moss C, Kaye SB: Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 38 (13): 1701-7, 2002.[PUBMED Abstract]

Muggia FM: Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132. Int J Gynecol Cancer 13 (Suppl 2): 156-62, 2003 Nov-Dec.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Medical Research Council Clinical Trials Unit

Peter Harper, MD, Protocol chair
Ph: 44-207-188-4255

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.